

Manual
For professional use only

ID-Vit[®] Niacin

***Microbiological test kit for the determination of total free
niacin (nicotinic acid/nicotinamid acid) in serum using a
Lactobacillus plantarum-coated microtiter plate
For use in human and veterinary medicine and in research***


Valid from 2025-03-28

REF KIF003

REF KIF003.2

Σ 96

Σ 2 x 96



IVD

CE



Immundiagnostik AG, Stubenwald-Allee 8a, 64625 Bensheim, Germany

Tel.: +49 6251 70190-0

Fax: + 49 6251 70190-363

e.mail: info@immundiagnostik.com www.immundiagnostik.com

Table of Contents

1. INTENDED PURPOSE	19
2. INTRODUCTION	19
3. PRINCIPLE OF THE TEST	20
4. MATERIAL SUPPLIED	21
5. MATERIAL REQUIRED BUT NOT SUPPLIED	21
6. PRECAUTIONS	21
7. STORAGE AND PREPARATION OF REAGENTS	22
7.1 Water	22
7.2 Preparation of the sterile assay medium	22
7.3 Preparation of the controls	23
7.4 Preparation of the standard curve	23
7.5 Microtiter plate [PLATE]	23
8. SAMPLE STORAGE AND PREPARATION	24
8.1 Sample dilution	24
9. ASSAY PROCEDURE	24
9.1 Test preparations	24
9.2 Test procedure	24
9.3 Measurement	25
10. EVALUATION OF RESULTS	25
10.1 Calculation	25
10.2 Quality control	26
11. LIMITATIONS	26
12. PERFORMANCE CHARACTERISTICS	26
12.1 Precision and reproducibility	26
12.2 Recovery	27
12.3 Linearity	28
13. GENERAL NOTES ON THE TEST AND TEST PROCEDURE	29
14. REFERENCES	30
15. SYMBOLS	30

Safety information

The assay has to be performed exclusively according to the instructions for use enclosed with the kit. Important safety information for this product can be found in the chapter PRECAUTIONS.

For Reference Use Only

1. INTENDED PURPOSE

ID-Vit® Niacin is a microtiter plate test kit based on a microbiological method which measures the total free niacin content in serum. The test kit contains the standard and all reagents required to perform the test. An ELISA reader is required for the evaluation of the results. For use in human and veterinary medicine and in research. For *in vitro* diagnostic use only.

2. INTRODUCTION

Niacin (nicotinic acid and nicotinamide) is used by the body to form coenzymes such as nicotinamide adenine dinucleotide (NAD⁺) and nicotinamide adenine dinucleotide phosphate (NADP⁺). As many as 200 enzymes require the two coenzymes, NAD⁺ and NADP⁺, mainly to accept or donate electrons for redox reactions. NAD⁺ functions most often in reactions involving the degradation (catabolism) of carbohydrates, fats, proteins, and alcohol to produce energy. NADP⁺ functions more often in biosynthetic (anabolic) reactions, such as in the synthesis of fatty acids and cholesterol. Since almost every metabolic pathway uses either NAD⁺ or NADP⁺, it is not surprising to find signs and symptoms of niacin deficiency in severe metabolic disorders. The worst of these is pellagra which is characterized by the four Ds, representing dermatitis, diarrhoea, dementia and death.

Niacin deficiency syndromes

Symptoms of minor niacin deficiency:

- Loss of appetite
- Depressiveness
- Dementia
- Insomnia
- Weakness
- Irritability

Severe niacin deficiency may cause pellagra. The term pellagra is derived from the Italian words “pelle agra” meaning “rough” or “smarting skin”. Pellagra is characterized by symptoms such as:

- Glossitis
- Sore, swollen, purple-red tongue
- Skin lesions primarily located on sun-exposed areas

Niacin as cholesterol lowering drug

Niacin increases HDL cholesterol and reduces LDL cholesterol and triglycerides. When taken in conjunction with another cholesterol medication, diet or exercise, niacin has been proven to reduce „bad“ cholesterol levels. A niacin-statin combination therapy substantially improves 4 major lipoprotein levels associated with atherosclerotic disease (Insull et al. 2004). The drug combination had good records in clinical trials for reduction in cardiovascular events and improvement in progression/regression of coronary lesions.

Indications

- Deeply pigmented skin on sun-exposed areas
- Alcohol abuse
- Dementia
- Dry skin and mouth
- Numbness of the extremities
- Inflammation of the mucous membranes of the tongue and mouth
- Digestive disorders

Niacin can be synthesized in the body from tryptophan, whereby the conversion requires the presence of thiamine, pyridoxine, and riboflavin. Any deficiency in these vitamins can affect the niacin metabolism.

3. PRINCIPLE OF THE TEST

The serum samples are diluted and then transferred into the wells of a microtiter plate coated with *Lactobacillus plantarum*. The addition of niacin in either standards or samples gives a niacin-dependent growth response until niacin is consumed. After incubation at **37 °C** for **46–50 h**, the growth of *Lactobacillus plantarum* is measured turbidimetrically at 610–630 nm (alternatively at 540–550 nm) in an ELISA reader and compared to a standard curve generated from the dilution series. The amount of niacin is directly proportional to the turbidity.

4. MATERIAL SUPPLIED

Cat. No.	Label	Kit components	Quantity	
			KIF003	KIF003.2
KIF000.30	DIL	Water	6 x 30 ml	7 x 30 ml
KIF003 KIF003.2	PLATE	<i>Lactobacillus plantarum</i> -precoated microtiter plate	1 x	2 x
	ASYMED	Niacin assay medium	4 x	4 x
	STD	Niacin standard, lyoph.	4 x	3 x
	FOL	Adhesive cover foil	1 x whole 3 x half	3 x whole
	FRA	Replacement holder for microtiter strips	1 x	1 x
	CTRL1	Niacin control 1, lyoph.	4 x	3 x
	CTRL2	Niacin control 2, lyoph.	4 x	3 x

5. MATERIAL REQUIRED BUT NOT SUPPLIED

- Incubator with a dark incubation chamber, 37 °C
- ELISA reader 610–630 nm (540–550 nm)
- Calibrated precision pipettors and sterile single use 20–1 000 µl tips
- 5 ml and 10 ml pipets
- 1.5–2 ml reaction vials
- 0.2 µm sterile polyethersulfone (PES) filter with a disposable syringe (10 ml)
- 15 ml centrifuge tubes (e.g. Falcon tubes)
- Biocentrifuge (10 000 g)
- Vortex

6. PRECAUTIONS

- The test is based on a microbiological method. Contaminations lead to erroneous results.
- Water quality is extremely important for the test. Use only the water delivered with the test kit (**DIL**).
- For sterile filtration, only a sterile polyethersulfone filter must be used.
- It is essential to run a standard curve for each separate assay.

- Measure controls with each assay.
- We recommend measurements in duplicate.
- Do not use reagents beyond the expiration date shown on the label.
- As a precaution, it is recommended that the human material used is always considered potentially infectious.
- Used microtiter stripes and materials that have been in contact with patient samples must be handled and disposed of as potentially infectious.

7. STORAGE AND PREPARATION OF REAGENTS

- Store test kit and reagents at 2–8°C.
- Prepare reagents freshly and use them immediately after preparation.
- To run the assay more than once, ensure that reagents are stored at the conditions stated on the label. Prepare only the appropriate amount necessary for each run. The kit can be used up to 3x (KIF003.2) or 4x (KIF003) within the expiry date stated on the label.

7.1 Water

- Water (**DIL**) for medium (**ASYMED**), standard (**STD**) , controls (**CTRL1**, **CTRL2**) and dilutions.
- Push the lid up and pull it back to the rim of the glass, then twist the whole cap off.

7.2 Preparation of the sterile assay medium

- Fresh sterile assay medium has to be prepared each time before performing a test.
- Remove the desiccant bag from the lyophilised assay medium bottle by taking the bag with a forceps and shaking it whilst still inside the bottle. Then remove the clean desiccant bag and discard it.
- Add 10 ml water (**DIL**) to the assay medium bottle (**ASYMED**), close the bottle firmly and vortex well. This amount is sufficient for 6 microtiter stripes.
- Filter the medium using a disposable syringe (10 ml) and the 0.2 µm PES filter into a centrifuge tube (15 ml, e.g. Falcon).

- After this preparation, the sterile assay medium can be used in the test.
- Note: Any suspended solids present in the assay medium, which are removed by the sterile filtration, have no impact on the measured values.

7.3 Preparation of the controls

- The lyophilised controls (**CTRL1**, **CTRL2**) have to be resuspended each with **x ml** water (**DIL**) (x = see product specification) from the test kit, then homogenise using a vortex.
- After reconstitution, the controls are treated like samples.
- The concentration of the controls changes from lot to lot and is stated in the product specification.

7.4 Preparation of the standard curve

- For the preparation of the standard curve, standard concentrate is needed. To prepare standard concentrate, resuspend the lyophilised standard (**STD**) with **x ml** water (**DIL**) (x = see quality control protocol) supplied with the test kit, then homogenise using a vortex.
- Prepare a standard curve in 6 sterile reaction tubes (1.5–2 ml volume) from standard concentrate and water (**DIL**) following the scheme depicted in the table below:

Niacin [µg/l]	Water (DIL) [µl]	+	Standard concentrate [µl]	=	Total volume [µl]
Blank: 0	500	+	0	=	500
Standard 1: 2	475	+	25	=	500
Standard 2: 8	400	+	100	=	500
Standard 3: 16	300	+	200	=	500
Standard 4: 24	200	+	300	=	500
Standard 5: 40	0	+	500	=	500

7.5 Microtiter plate [PLATE]

- Store the microtiter plate (**PLATE**) in the aluminium packaging containing the desiccant bag at 2–8 °C.
- The microtiter plate (**PLATE**) has to be protected from humidity and contamination.

- Take care that the aluminium packaging is not damaged.
- Carefully close the aluminium packaging after opening.
- Take only the microtiter stripes needed directly before usage to avoid contamination.

8. SAMPLE STORAGE AND PREPARATION

- Use serum for analysis.
- Samples are stable at 2–8°C for three days in the dark. For longer storage, samples can be frozen and kept at -20°C for up to 5 months.
- Centrifuge samples prior to measurement (at least 5 min at 10 000 *g*). Use the resulting supernatant in the test.
- Do not use hemolytic samples for analysis as they may give erroneous results. Centrifuge lipemic samples at 13 000 *g* for 10 min before assaying to obtain a serum that is as fat free as possible.

8.1 Sample dilution

Take 100 µl from the sample/control, add 300 µl water (**DIL**) and mix. This results in a total dilution of 1:4 (= sample dilution factor).

9. ASSAY PROCEDURE

9.1 Test preparations

Take as many microtiter strips as needed from kit. Return unused strips and any unused test kit components to the original packaging, and store in the refrigerator. Bring all necessary reagents to room temperature.

9.2 Test procedure

- Take as many microtiter strips as needed from the kit and put them in the second microtiter strip holder (**FRA**).
- Put 150 µl sterile assay medium into each cavity.

- Add 150 µl of the prepared standard dilutions (blank, standard 1–5), samples and controls into the respective cavities. Pre-rinse each pipet tip with standard, control or sample solution, respectively.
- Carefully seal the plate with adhesive cover foil (**FOL**). Important: the cavities must be made airtight by pressing the foil down with the hand!
- Keep at **37 °C** for **46–50 h** in an incubator.

9.3 Measurement

- Press the adhesive cover foil (**FOL**) firmly down again with the hand.
- Turn the microtiter plate (**PLATE**) upside down, place it onto a tabletop and shake the microbes well.
- Turn the microtiter plate (**PLATE**) over again and carefully remove the adhesive cover foil (**FOL**). During this, fix the strips in the frame with your hand because the foil is highly adhesive.
- Remove air bubbles in the cavities using a pipet tip or a needle.
- Read turbidity in an ELISA reader at E 610–630 nm (alternatively at E 540–550 nm).

Please note

- After 46–50 h incubation time, the microtiter plate (**PLATE**) may be stored for a maximum of 48 h in the refrigerator before measuring the turbidity.

10. EVALUATION OF RESULTS

We recommend to use the 4 parameter algorithm to calculate the results. The sample dilution factor has to be considered for data evaluation.

The blank serves as a visual control to exclude contamination and is not taken into account in the calculation. The optical density must be < standard 1. If this is not the case, the analysis must be carried out again.

10.1 Calculation

Niacin in µg/l = value from the standard curve × sample dilution factor (4)

Reference value for human serum

Based on studies of serum samples of apparently healthy persons ($n = 83$), the following values were estimated.

Niacin: 17–85 µg/l (Mean \pm 2 SD)

Please note

A concentration range of 8–160 µg/l niacin is covered at a sample dilution of 1:4.

We recommend each laboratory to develop its own normal range as normal ranges strongly depend on the choice of the patient collective. The values mentioned above are only for orientation and can deviate from other published data.

10.2 Quality control

The extinction of the highest standard has to be > 0.6 .

Results, generated from the analysis of control samples, should be evaluated for acceptability. The results for the samples may not be valid if within the same assay one or more values of the quality control sample or the highest standard are outside the acceptable limits.

11. LIMITATIONS

Only serum can be used in the assay.

12. PERFORMANCE CHARACTERISTICS

The following performance characteristics have been collected using human serum samples.

12.1 Precision and reproducibility

Intraassay ($n = 6$)

	Niacin [µg/l]	CV [%]
Sample	64	2.9

Interassay ($n = 5$)

	Niacin [µg/l]	CV [%]
Sample	64	3.4

12.2 Recovery

Samples from 4 patients were diluted differently (20, 40, 80, 120, 160), spiked with niacin and analysed. The mean values are shown below.

Sample (n=9)	Mean value original sample [µg/l]	Spike [µg/l]	Niacin expected [µg/l]	Niacin measured [µg/l]	Recovery Rate [%]
A	21.5	60	81.5	77	93
		120	141.5	134	94
		180	201.5	203	101
Recovery rate in total [%]					96

Sample (n=9)	Mean value original sample [µg/l]	Spike [µg/l]	Niacin expected [µg/l]	Niacin measured [µg/l]	Recovery Rate [%]
B	16.9	60	76.9	76	99
		120	136.9	136	100
		180	196.9	199	101
Recovery rate in total [%]					100

Sample (n=9)	Mean value original sample [µg/l]	Spike [µg/l]	Niacin expected [µg/l]	Niacin measured [µg/l]	Recovery Rate [%]
C	19.9	60	79.9	79	99
		120	139.9	145	104
		180	199.9	203	102

Recovery rate in total [%]

102

Sample (n=9)	Mean value original sample [µg/l]	Spike [µg/l]	Niacin expected [µg/l]	Niacin measured [µg/l]	Recovery Rate [%]
D	18.3	60	78.3	82	106
		120	138.3	139	100
		180	198.3	195	98

Recovery rate in total [%]

102

12.3 Linearity

Samples from 2 patients were diluted and analyzed. The results are shown below.

Sample	Dilution	Niacin expected [µg/l]	Niacin detected [µg/l]
A	4	128	128
	8		138
	16		137

Sample	Dilution	Niacin expected [µg/l]	Niacin detected [µg/l]
D	8	196	196
	16		193
	24		203
	32		188

13. GENERAL NOTES ON THE TEST AND TEST PROCEDURE

- This assay was produced and distributed according to the IVD guidelines of 98/79/EC.
- All reagents in the kit package are for *in vitro* diagnostic use only.
- ID-Vit® is a trademark of Immundiagnostik AG.
- Reagents should not be used beyond the expiration date stated on the kit label.
- Do not interchange different lot numbers of any kit component within the same assay.
- The guidelines for medical laboratories should be followed.
- Incubation time, incubation temperature and pipetting volumes of the components are defined by the producer. Any variation of the test procedure, which is not coordinated with the producer, may influence the results of the test. Immundiagnostik AG can therefore not be held responsible for any damage resulting from incorrect use.
- Warranty claims and complaints regarding deficiencies must be logged within 14 days after receipt of the product. The product should be sent to Immundiagnostik AG along with a written complaint.
- Control samples should be analysed with each run.
- The assay should always be performed according to the enclosed manual.

14. REFERENCES

- 1. Strohecker, R. & Henning, H., **1963**. Vitamin-Bestimmungen. Erprobte Methoden. Weinheim/Bergstraße: *Verlag Chemie GmbH*.
- 2. Singer, D. et al., 2012. Defective intestinal amino acid absorption in Ace2 null mice. American journal of physiology. *Gastrointestinal and liver physiology*, **303**(6), pp.G686-95.
- 3. Morris, M.C. et al., 2004. Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline. *Journal of neurology, neurosurgery, and psychiatry*, **75**(8), pp.1093-9.

15. SYMBOLS



Temperature limitation



Catalogue number



In Vitro Diagnostic Medical Device



To be used with



Manufacturer



Content sufficient for <n> tests



Lot number



Use by



Contains plasma derivatives or human blood



Consult instructions for use



Consult specification data sheet



Do not re-use



Unique Device Identification



Contains material of animal origin



Medicinal substance



Contains material of human origin

For Reference Use Only

For Reference Use Only

For Reference Use Only

Immundiagnostik AG

Stubenwald-Allee 8a
64625 Bensheim, Germany

Tel.: +49 6251 70190-0

Fax: +49 6251 70190-363

info@immundiagnostik.com

www.immundiagnostik.com

